General Information of Drug Off-Target (DOT) (ID: OT0G3KEQ)

DOT Name Hyaluronan and proteoglycan link protein 2 (HAPLN2)
Synonyms Brain link protein 1
Gene Name HAPLN2
Related Disease
Neoplasm ( )
Parkinson disease ( )
Schizophrenia ( )
UniProt ID
HPLN2_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Pfam ID
PF07686 ; PF00193
Sequence
MPGWLTLPTLCRFLLWAFTIFHKAQGDPASHPGPHYLLPPIHEVIHSHRGATATLPCVLG
TTPPSYKVRWSKVEPGELRETLILITNGLHARGYGPLGGRARMRRGHRLDASLVIAGVRL
EDEGRYRCELINGIEDESVALTLSLEGVVFPYQPSRGRYQFNYYEAKQACEEQDGRLATY
SQLYQAWTEGLDWCNAGWLLEGSVRYPVLTARAPCGGRGRPGIRSYGPRDRMRDRYDAFC
FTSALAGQVFFVPGRLTLSEAHAACRRRGAVVAKVGHLYAAWKFSGLDQCDGGWLADGSV
RFPITTPRPRCGGLPDPGVRSFGFPRPQQAAYGTYCYAEN
Function
Mediates a firm binding of versican V2 to hyaluronic acid. May play a pivotal role in the formation of the hyaluronan-associated matrix in the central nervous system (CNS) which facilitates neuronal conduction and general structural stabilization. Binds to hyaluronic acid.
Tissue Specificity Expressed only in adult brain.

Molecular Interaction Atlas (MIA) of This DOT

3 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Neoplasm DISZKGEW Definitive Biomarker [1]
Parkinson disease DISQVHKL Strong Biomarker [2]
Schizophrenia DISSRV2N Strong Altered Expression [2]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
3 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Acetaminophen DMUIE76 Approved Acetaminophen decreases the expression of Hyaluronan and proteoglycan link protein 2 (HAPLN2). [3]
Triclosan DMZUR4N Approved Triclosan decreases the expression of Hyaluronan and proteoglycan link protein 2 (HAPLN2). [5]
Fluorouracil DMUM7HZ Approved Fluorouracil affects the expression of Hyaluronan and proteoglycan link protein 2 (HAPLN2). [6]
------------------------------------------------------------------------------------
3 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Arsenic DMTL2Y1 Approved Arsenic affects the methylation of Hyaluronan and proteoglycan link protein 2 (HAPLN2). [4]
Fulvestrant DM0YZC6 Approved Fulvestrant decreases the methylation of Hyaluronan and proteoglycan link protein 2 (HAPLN2). [7]
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene increases the methylation of Hyaluronan and proteoglycan link protein 2 (HAPLN2). [8]
------------------------------------------------------------------------------------

References

1 Reduced expression of the hyaluronan and proteoglycan link proteins in malignant gliomas.J Biol Chem. 2009 Sep 25;284(39):26547-56. doi: 10.1074/jbc.M109.013185. Epub 2009 Jul 24.
2 Hapln2 in Neurological Diseases and Its Potential as Therapeutic Target.Front Aging Neurosci. 2019 Mar 21;11:60. doi: 10.3389/fnagi.2019.00060. eCollection 2019.
3 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
4 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
5 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
6 Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics. 2006 Apr 3;7:68. doi: 10.1186/1471-2164-7-68.
7 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
8 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.